Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses

Clinical Infectious Diseases

Volumn 33, Issue 1, 2001, Pages 95-106

  Tollemar, Jan ^w  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^k FLORIDA HOSPITAL   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MANITOBA   (Canada)

^o Asesoria Cientifica y de Investigacion Aplicada   (Spain)

^p HÔPITAL DU BOCAGE   (France)

^q UNIVERSITY OF MANCHESTER   (United Kingdom)

^r RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^s SAPIENZA UNIVERSITY OF ROME   (Italy)

^t UNIVERSITY OF GENOA   (Italy)

^u Ist di Igiene e Medicina Preventiva   (Italy)

^v European Organisation of Research and Treatment of Cancer   (Belgium)

^w KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DISEASE MARKER; MYCOSIS; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CONTROLLED CLINICAL TRIALS; HUMANS; MYCOSES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0034983131     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320876     Document Type: Review

References (109)

1. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?
2. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
3. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis
4. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
5. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients
6. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial
7. Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo
8. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
9. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks
10. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
11. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
12. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome
13. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
14. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome
15. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
16. Ketoconazole therapy of progressive coccidioidomycosis: Comparison of 400- and 800-mg doses and observations at higher doses
17. A comparison of oral fluconazole or itraconazole for progressive, nonmeningeal coccidioidomycosis
18. Treatment of blastomycosis and histoplasmosis with ketoconazole: Results of a prospective, randomized clinical trial
19. Itraconazole therapy for blastomycosis and histoplasmosis
20. Treatment of blastomycosis with fluconazole: A pilot study
21. Treatment of blastomycosis with higher doses of fluconazole
22. Fluconazole therapy for histoplasmosis
23. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study
24. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole
25. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole
26. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: A prospective, randomized, double-blind study
27. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
28. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: Results of a randomized placebo-controlled, double-blind, multicenter trial
29. A randomised controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies
30. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial
31. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
32. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
33. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. Amphotericin B in the empirical treatment of fever and neutropenia
34. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: A pragmatic, multicentre, prospective and randomised clinical trial
35. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: A randomised comparative study with amphotericin B
36. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: A randomized, placebo-controlled study
37. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation
38. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial
39. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
40. Blastomycosis. III. A comparative study of 2-hydroxystilbamidine and amphotericin B therapy
41. Prognostic factors in cryptococcal meningitis: A study in 111 cases
42. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens
43. Early diagnosis of invasive aspergillosis
44. Aspergillus fumigatus and aspergillosis
45. When to base clinical policies on observational versus randomized trial data
46. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria
47. Emergency use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: Historical control comparison with amphotericin B
48. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
49. Progressive disseminated histoplasmosis: A prospective study of 26 patients
50. Disseminated histoplasmosis: Results of long-term follow-up: A Center for Disease Control Cooperative Mycoses Study
51. Favorable outcome of invasive aspergillosis in patients with acute leukemia
52. Phase 1 study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant
53. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS
54. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients
55. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome
56. Practice guidelines for the management of patients with sporotrichosis
57. Practice guidelines for the management of patients with histoplasmosis
58. Treatment of Candida albicans fungaemia with fluconazole
59. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections
60. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS
61. Bias in treatment assignment in controlled clinical trials
62. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
63. Predictors of adverse outcome in cancer patients with candidemia
64. Risk factors for hospital-acquired candidemia: A matched case-control study
65. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables
66. The promise and problems of meta-analysis
67. Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: A randomized, double-blind study
68. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
69. Fungal infections in iatrogenically compromised hosts
70. Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum d-arabinitol
71. Rapid diagnosis of candidiasis and aspergillosis
72. Current trends in immunodiagnosis of candidiasis and aspergillosis
73. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis: Disseminated versus single-organ infection
74. Candida colonization and subsequent infections in critically ill surgical patients
75. Prospective multicenter surveillance study of funguria in hospitalized patients
76. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
77. Two strategies for managing invasive aspergillosis: A decision analysis
78. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
79. Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections
80. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis
81. Detection and identification of fungal pathogens in blood by using molecular probes
82. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis
83. PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies
84. Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis
85. Diagnosis of invasive candidiasis in neutropenic children with cancer by determination of d-arabinitol/l-arabinitol ratios in urine
86. Rapid detection of Candida albicans in clinical samples by DNA amplication of common regions from C. Albicans-secreted aspartic proteinase genes
87. Assessment of detection of Candida mannoproteinemia as a method to differentiate central venous catheter-related candidemia from invasive disease
88. Enolase antigen, mannan antigen, CandTec antigen, and β-glucan in patients with candidemia
89. Plasma (1-3)-β-d glucan and fungal antigenenia in patients with candidemia, aspergillosis and cryptococcosis
90. Panfungal PCR assay for detection of fungal infection in human blood specimens
91. Evaluation of active control trials in AIDS
92. Antibiotic clinical trials: The Witley Park Symposium
93. A comparison of observational studies and randomized, controlled trials
94. Randomized, controlled trials, observational studies, and the hierarchy of research designs
95. Randomized trials or observational tribulations?